What are the types of necrotizing fasciitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Types of Necrotizing Fasciitis

Necrotizing fasciitis is traditionally classified into two main microbiological types: Type I (polymicrobial infection) and Type II (monomicrobial infection), though emerging evidence suggests monomicrobial Gram-negative infections may warrant recognition as a distinct subtype.

Type I: Polymicrobial Necrotizing Fasciitis

Type I is the more prevalent form, characterized by polymicrobial infection involving both aerobic and anaerobic organisms 1. The causative pathogens typically include:

  • Aerobic bacteria: Coliforms (E. coli, Klebsiella, Proteus)
  • Anaerobic bacteria: Bacteroides, Peptostreptococcus, Clostridium species
  • Average of 5 different pathogens cultured from each wound 1

Most organisms originate from bowel or genitourinary flora, making this type particularly common in perineal, perirectal, and abdominal wall infections 1. This classification has remained consistent in the IDSA guidelines 1.

Type II: Monomicrobial Necrotizing Fasciitis

Type II involves single bacterial pathogens, most classically:

  • Group A β-hemolytic Streptococcus (Streptococcus pyogenes) - the prototypical organism 2, 3
  • Also referred to as "streptococcal gangrene" or "flesh-eating bacteria syndrome" 3
  • Often associated with streptococcal toxic shock syndrome 1

This type frequently occurs in previously healthy individuals and can develop from minor trauma or have no identifiable portal of entry 4.

Emerging Classification: Monomicrobial Gram-Negative Subtype

Recent global epidemiological data strongly supports recognizing monomicrobial Gram-negative (mono-GNB) infections as a distinct entity 5. Key findings include:

  • Proportion increased from 12% before 2000 to 18% from 2000 onward globally 5
  • Highest in-hospital mortality (28% before 2000,22% from 2000 onward) among all subtypes 5
  • Particularly prevalent in WHO Western Pacific, South-East Asia, and Africa regions 5
  • Common causative organisms include Pseudomonas aeruginosa, E. coli, Klebsiella pneumoniae, and Acinetobacter species 6, 5

Clinical Implications of This Emerging Pattern

The rising prevalence of mono-GNB infections has critical treatment implications. In regions with high mono-GNB prevalence, empiric antimicrobial regimens must include prompt Gram-negative coverage 5. This is particularly important given that:

  • Multidrug-resistant (MDR) organisms are increasingly common (19% prevalence in one series) 6
  • MDR Pseudomonas, Klebsiella, and Acinetobacter are frequently isolated 6
  • Extended-spectrum β-lactamase (ESBL)-producing organisms complicate treatment 6

Additional Historical Classifications

Some literature references Type III (gas gangrene from Clostridium species) and Type IV (fungal), though these are less commonly used in current clinical practice and are not emphasized in major guidelines 1.

Practical Clinical Approach

When encountering necrotizing fasciitis, the microbiological classification should guide empiric antibiotic selection:

  • For polymicrobial (Type I): Broad-spectrum coverage including MRSA and anaerobes with vancomycin/linezolid/daptomycin PLUS piperacillin-tazobactam, carbapenem, or ceftriaxone plus metronidazole 1

  • For suspected streptococcal (Type II): Clindamycin PLUS penicillin (clindamycin suppresses toxin production and is superior to penicillin alone in animal models) 1

  • In high mono-GNB prevalence regions: Ensure empiric regimen includes robust Gram-negative coverage, particularly anti-pseudomonal agents 5

Critical Caveat

The distribution of Type I versus Type II is nearly equal in some contemporary series (51% vs 49%) 6, contrasting with older literature suggesting Type I predominance. This underscores the importance of regional epidemiological awareness and the need to tailor empiric therapy to local resistance patterns 6, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.